Publication | Closed Access

Adding ascorbic acid to arsenic trioxide produces limited benefit in patients with acute myeloid leukemia excluding acute promyelocytic leukemia

Ascorbic AcidHematological MalignancyBiochemistryMedicineAcute Myeloid LeukemiaMixed-phenotype Acute LeukemiaHematologyMyeloid NeoplasiaMalignant Blood DisorderPharmacologyRadiation OncologyAcute Promyelocytic LeukemiaOxidative StressHealth Sciences